Siemens MicroScan Synergies Plus And MicroScan RapID/S Plus Negative Panels: Class I Recall - False Susceptible And False Intermediate Results Defect may lead to treatment with an inappropriate antibiotic or a delay in initiating appropriate therapy. Lingua Inglese Leggi tutto su Siemens MicroScan Synergies Plus And MicroScan RapID/S Plus Negative Panels: Class I Recall - False Susceptible And False Intermediate Results
Zolpidem and Driving Impairment — Identifying Persons at Risk Leggi tutto su Zolpidem and Driving Impairment — Identifying Persons at Risk
Irreversible Blindness Following Intravenous Streptokinase Leggi tutto su Irreversible Blindness Following Intravenous Streptokinase
Dermatomyositis Induced by Anti alfa Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis Leggi tutto su Dermatomyositis Induced by Anti alfa Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis
Use of Potentially Harmful Skin-Lightening Products among Immigrant Women in Rome, Italy: A Pilot Study Leggi tutto su Use of Potentially Harmful Skin-Lightening Products among Immigrant Women in Rome, Italy: A Pilot Study
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Leggi tutto su Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme
Comparative Mortality Risk in Adult Patients With Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, and Attention-Deficit/Hyperactivity Disorder Participating in Psychopharmacology Clinical Trials Leggi tutto su Comparative Mortality Risk in Adult Patients With Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, and Attention-Deficit/Hyperactivity Disorder Participating in Psychopharmacology Clinical Trials
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy Leggi tutto su Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy
